Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126218241 | 12621824 | 1 | I | 20160623 | 20160728 | 20160804 | 20160804 | EXP | FR-GE HEALTHCARE MEDICAL DIAGNOSTICS-VISP-PR-1607S-0447 | GE HEALTHCARE | 78.17 | YR | F | Y | 0.00000 | 20160804 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126218241 | 12621824 | 1 | PS | VISIPAQUE | IODIXANOL | 1 | Intravenous (not otherwise specified) | 20351 | 10 | ML | SOLUTION FOR INJECTION | ||||||||
| 126218241 | 12621824 | 2 | SS | VISIPAQUE | IODIXANOL | 1 | 20351 | ||||||||||||
| 126218241 | 12621824 | 3 | SS | MIDAZOLAM | MIDAZOLAMMIDAZOLAM HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 0 | QD | ||||||||||
| 126218241 | 12621824 | 4 | SS | XYLOCAINE | LIDOCAINE HYDROCHLORIDE | 1 | Subcutaneous | 0 | QD | ||||||||||
| 126218241 | 12621824 | 5 | C | DUROGESIC | FENTANYL | 1 | Transdermal | 0 | |||||||||||
| 126218241 | 12621824 | 6 | C | PANTOPRAZOLE | PANTOPRAZOLE SODIUM | 1 | 0 | ||||||||||||
| 126218241 | 12621824 | 7 | C | SPIRIVA | TIOTROPIUM BROMIDE MONOHYDRATE | 1 | 0 | ||||||||||||
| 126218241 | 12621824 | 8 | C | LASILIX | FUROSEMIDE | 1 | 0 | ||||||||||||
| 126218241 | 12621824 | 9 | C | CACIT VITAMIN D3 | CALCIUM CARBONATECHOLECALCIFEROL | 1 | 0 | ||||||||||||
| 126218241 | 12621824 | 10 | C | FOSAVANCE | ALENDRONATE SODIUMCHOLECALCIFEROL | 1 | 0 | ||||||||||||
| 126218241 | 12621824 | 11 | C | DAFALGAN | ACETAMINOPHEN | 1 | 0 | ||||||||||||
| 126218241 | 12621824 | 12 | C | CIPROFIBRATE | CIPROFIBRATE | 1 | 0 | ||||||||||||
| 126218241 | 12621824 | 13 | C | GLICLAZIDE | GLICLAZIDE | 1 | 0 | ||||||||||||
| 126218241 | 12621824 | 14 | C | LORAZEPAM. | LORAZEPAM | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126218241 | 12621824 | 1 | Product used for unknown indication |
| 126218241 | 12621824 | 2 | Diagnostic procedure |
| 126218241 | 12621824 | 3 | Sedation |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126218241 | 12621824 | LT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126218241 | 12621824 | Abdominal distension | |
| 126218241 | 12621824 | Anaphylactic shock | |
| 126218241 | 12621824 | Bradycardia | |
| 126218241 | 12621824 | Cardio-respiratory arrest | |
| 126218241 | 12621824 | Feeling hot |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126218241 | 12621824 | 1 | 20160623 | 20160623 | 0 | |
| 126218241 | 12621824 | 3 | 20160623 | 20160623 | 0 | |
| 126218241 | 12621824 | 4 | 20160623 | 20160623 | 0 |